UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden

hours per response:

0.5

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

09/12/2019

3. Issuer Name and Ticker or Trading Symbol

SpringWorks Therapeutics, Inc.

[ SWTX ]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

5. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr.

4)

2.

Amount of Securities Beneficially Owned (Instr.

4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr.

5)

4. Nature of Indirect Beneficial Ownership (Instr.

5)

Table II - Derivative Securities Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

4)

2. Date Exercisable and Expiration Date

(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security (Instr.

4)

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form: Direct (D) or Indirect (I) (Instr.

5)

6. Nature of Indirect Beneficial Ownership (Instr.

5)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Junior Series A Convertible Preferred Stock

(1)

(1)

Common Stock

978,194

(1)

D(4)

Series A Convertible Preferred Stock

(2)

(2)

Common Stock

3,039,051

(2)

D(4)

Series B Convertible Preferred Stock

(3)

(3)

Common Stock

526,602

(3)

D(4)

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

1. Name and Address of Reporting Person*Pfizer Ventures (US) LLC

(Last)

(First)

(Middle)

235 EAST 42ND STREET

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

Explanation of Responses:

1. Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer Inc. ("Pfizer").

2. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer.

3. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock will convert into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Such shares are held of record by Pfizer Ventures (US) LLC, a wholly-owned subsidiary of Pfizer.

4. Each Reporting Person disclaims ownership of securities held by each other Reporting Person, except to the extent of its respective pecuniary interest therein.

Pfizer Inc., By /s/ Susan Grant, Assistant Secretary

09/12/2019

Pfizer Ventures (US) LLC, By /s/ Susan Grant, Secretary

09/12/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.